Skip to main content
Journal of Experimental Orthopaedics

Table 1 Synopsis of clinical studies on scaffold-based meniscal substitutes (chronological order)

From: Meniscal substitution, a developing and long-awaited demand

Author

Year

N

Age|

♂ / ♀

FU

Scaffold

M/L

A/C

Size||

Assoc. Procedures

Radiologic Outcomes

Clinical Outcomes

   

[years]

 

[months]

   

[mm]

[%]

  

Toanen [67]

2020

155

34

109/46

60

Actifit®

101/54

14/141

39.4

HTO (28), ACLR (19), CS (4)

Genovese score, extrusion, ICRS

VAS, LS, IKDC, KOOS, survival rate

Schenk [68]

2019

39

34

30/9

36

CMI

32/7

25/14

48

ACLR (62)

Genovese score, extrusion

VAS, LS, IKDC, Tegner, clinical failure

Monllau [69]

2018

32

41

25/7

70.8

Actifit®

21/11

N/A

40.9

ACLR (28), HTO (41), PCLR (3), CS (44)

Genovese score, extrusion, volume

LS, IKDC, KOOS, Tegner,

Leroy [70]

2017

15

30

8/7

72

Actifit®

6/9

0/15

N/A

ACLR (33), CS (7)

Genovese score, extrusion, ICRS

VAS, IKDC, KOOS, failure rate

Dhollander [71]

2016

44

32

24/20

60

Actifit®

29/15

4/40

45.5

ACLR (9), HTO (9)

Genovese score, extrusion, ICRS

VAS, IKDC, KOOS, survival rate

Filardo [72]

2016

16

45

9/7

72

Actifit®

12/4

N/A

N/A

ACLR (38), HTO (13), ME (94), CS (13), O (6)

Genovese score, extrusion

IKDC, Tegner

Schüttler [73]

2015

18

33

N/A

48

Actifit®

18/0

0/18

44.5

None

Genovese score, extrusion

VAS, KOOS, KSS, UCLA

Faivre [74]

2015

20

29

N/A

24

Actifit®

8/12

0/20

N/A

Ligament reconstruction (20), CS (15)

Signal intensity, extrusion, cartilage coverage index

IKDC, KOOS

Martín-Hernández [75]

2015

10

31

4/6

24

Actifit®

9/1

0/10

N/A

None

Genovese score, extrusion

VAS, LS, KOOS

Schüttler [76]

2015

18

33

N/A

24

Actifit®

18/0

0/18

40.9

None

Genovese score, extrusion

VAS, KOOS, KSS, UCLA

Baynat [77]

2014

18

20–46

13/5

24

Actifit®

13/5

0/18

N/A

ACL (56), HTO (56)

Genovese score, extrusion

LS, Histology

Gelber [78]

2014

30

51

40/20

31.2

Actifit®

60/0

0/60

40.3

HTO (100)

Radiographic evaluation of limb alignment and tibial slope

VAS, IKDC, Kujala, WOMET,

Bouyarmane [79]

2014

54

28

37/17

24

Actifit®

0/54

0/54

43

ACLR (17), DFO (9)

N/A

VAS, IKDC, KOOS

Kon [80]

2014

18

45

11/7

24

Actifit®

13/5

1/17

N/A

ACLR (17), Osteotomy (22), CS (39), O (17)

Genovese score

IKDC, Tegner

De Coninck [81]

2013

26

35

12/12

24

Actifit®

18/8

N/A

43.2

ACLR (23), HTO (4), DFO (4), CS (4), MAT (4)

Meniscal rim thickness, extrusion

VAS, LS, IKDC, KOOS

Bulgheroni [82]

2013

20

33

17/2

24–46

Actifit®

17/3

0/20

43/37**

ACLR (47), HTO (37), DFO (5)

Genovese score

VAS, LS, Tegner, second-look

Hirschmann [83]

2013

67

36

47/20

12

CMI

55/12

42/25

N/A

ACLR (67), HTO (7), CS (4)

Genovese score, extrusion

VAS, LS, IKDC, Tegner, clinical failure

Zaffagnini [84]

2012

24

36

20/4

26

CMI

0/24

7/17

45.2

ACLR (17), CS (25), O (4)

Genovese score, Yulish score

VAS, LS, IKDC, Tegner, EQ-5D

Efe [85]

2012

10

29

8/2

12

Actifit®

10/0

0/10

39.2

None

Genovese score, bone bruise, ICRS, remaining meniscus

VAS, KOOS, KSS, UCLA

Verdonk [86]

2012

52

31

39/13

24

Actifit®

34/18

2/46 (4 unknown)

47.1

ACLR (4)

ICRS

VAS, LS, IKDC, KOOS, SAE

Verdonk [55]

2011

52

31

39/13

12

Actifit®

34/18

2/46 (4 unknown)

47.1

N/A

Tissue ingrowth (DCE-MRI), ICRS

Pain, functionality, quality of life, Histology

Zaffagnini

2011

17

40

33/0

133

CMI

33/0

17/16

36

ACLR (12)

Genovese score, Yulish score, Radiographic evaluation

VAS, LS, IKDC, Tegner, SF-36

Monllau [87]

2011

25

29

20/5

133.2

CMI

25/0

20/5

48.2

ACLR (56), CS (4)

Genovese score, radiographic progression of OA

VAS, LS, failure rate,

Bulgheroni [88]

2010

34

39

25/9

60

CMI

34/0

6/28

45

ACLR (32), HTO (6), CS (3)

Genovese score, Yulish score, radiographic progression of OA

LS, Tegner, Histology

Rodkey [61]

2008

160

39

243/68

59

CMI

311/0

157/154

N/A

ACLR (27)

N/A

VAS, LS, Tegner, Histology

Linke [89]

2007

23

42

N/A

24

CMI

23/0

N/A

N/A

HTO (100)

N/A

VAS, LS, IKDC

Genovese [90]

2007

40

41

27/13

12–24

CMI

40/0

28/12

N/A

ACLR (40), HTO (3), CS (4)

Genovese score

N/A

Steadman [91]

2005

8

40

8/0

69.6

CMI

8/0

1/8

N/A

None

Signal intensity, interface, cartilage, bone marrow, radiographic evaluation of OA

VAS, LS, IKDC, Tegner, Histology

Rodkey [92]

1999

8

40

N/A

24

CMI

8/0

1/7

42.5

None

Morphology, size, radiographic progression of OA

VAS, LS, Tegner, Histology

Stone [54]

1997

10

39

8/2

36

CMI

10/0

4/6

N/A

ACLR (20)

Signal intensity, interface, radiographic evaluation of OA

VAS, activity + performance score, overall knee rating, Histology

  1. Abbreviations: A/C Acute/chronic; ACLR Anterior cruciate ligament reconstruction; CMI Collagen meniscus implant; CS Cartilage surgery; DCE-MRI Dynamic contrast-enhanced magnetic resonance imaging; DFO Distal femoral osteotomy; EQ-5D EuroQuol 5 dimensions; FU Follow-up; HTO High tibial osteotomy; ICRS International cartilage repair society; IKDC International knee documentation committee; KOOS Knee injury and osteoarthritis outcome score; KSS Knee society score; LS Lysholm score; M/L, medial/lateral; MAT Meniscal allograft transplantation; ME Meniscectomy; N Number of patients treated with scaffold-based meniscal substitutes; N/A Not available; O Others; OA Osteoarthritis; PCLR Posterior cruciate ligament reconstruction; SAE Scaffold-related serious adverse events; SF-36 Short form 36; UCLA University of California, Los Angeles activity scale; VAS Visual analogue scale; WOMET Western Ontario meniscal evaluation tool; |,mean age at surgery; ||, mean defect size
Back to article page